Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling.

Cell reports. Medicine·2026

Same author

Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma.

JTO clinical and research reports·2026

Same author

Development of novel GPC2-directed radiotheranostics and CAR T cell therapy for neuroblastoma.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Same author

Ablation of glypican-3 enhances radiosensitivity in liver cancer by prolonging G2/M arrest and activating the ATM/CHK2 pathway.

bioRxiv : the preprint server for biology·2026

Same author

Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.

JAMA·2026

Same author

A Novel CD147-Targeting Nanobody for Immuno-PET Imaging of Liver Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Search research articles

Related Experiment Video

Updated: Jun 29, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

National Cancer Institute support for targeted alpha-emitter therapy.

Julie A Hong¹, Martin Brechbiel², Jeff Buchsbaum¹

¹Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 9609 Medical Center Dr., Bethesda, MD, 20892, USA.

European Journal of Nuclear Medicine and Molecular Imaging

|August 11, 2021

Summary

This summary is machine-generated.

The National Cancer Institute (NCI) actively supports radiopharmaceutical targeted therapy (RPT) development through funding, research initiatives, and community engagement. This commitment aims to generate robust evidence for bringing RPT to cancer patients.

Keywords:

National Cancer Institute Radiopharmaceutical targeted therapy Targeted alpha-emitter therapy

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: Jun 29, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Area of Science:

Oncology
Nuclear Medicine
Radiopharmaceutical Therapy

Background:

Radiopharmaceutical targeted therapy (RPT) has a long history, with recent clinical trials showing efficacy driving renewed interest.
The modality involves using radioactive drugs to target cancer cells.

Purpose of the Study:

To review the National Cancer Institute (NCI)'s multifaceted support for radiopharmaceutical targeted therapy (RPT).
To highlight NCI's role in advancing RPT research from preclinical to clinical stages.

Main Methods:

Review of NCI's initiatives including workshops, interest groups, extramural funding (academia, small business), and intramural research.
Examination of NCI's support mechanisms like Research and Program Grants (RPG), Small Business Innovation Research (SBIR), and the Cancer Therapy Evaluation Program (CTEP).

Main Results:

NCI has fostered RPT community development through workshops and interest groups, focusing on dosimetry and rigorous studies.
Funding has been provided through RPG and SBIR, leading to clinical trials, with CTEP supporting RPT in clinical trials.
Intramural research, including preclinical targeted alpha-emitter therapy (TAT), is ongoing, leveraging NIH Clinical Center infrastructure.

Conclusions:

The NCI is committed to advancing radiopharmaceutical targeted therapy (RPT) development.
Continued support aims to generate high-quality evidence for patient treatment.
The goal is to facilitate the multidisciplinary advancement of RPT.